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  EGFR and ERBB2 belong to the EGFR gene family. In esophageal squamous cell 
carcinomas (SCCs), amplification of EGFR or ERBB2 is usually mutually exclusive. 
EGFR amplification occurs in approximately 15% of SCCs, ERBB2 occurs in less 
than 5%. Here, we report the co-amplification of EGFR and ERBB2 in an 
ulcerative and infiltrating-type SCC that measured approximately 4.2x2.7x1.2 cm 
with a superficial lesion occurring in the thoracic esophagus of a 72-year-old man. 
Multiplex ligation-dependent probe amplification using representative tumor 
sections showed gain of CCND1 and coincident amplification of ERBB2 or EGFR 
or neither. Immunohistochemistry and fluorescence in situ hybridization revealed 
that the tumor comprised three cancer-cell populations: well-differentiated SCC 
with high-level ERBB2 amplification and ERBB2 overexpression, more infiltrative 
poorly-differentiated SCC with high-level EGFR amplification and EGFR 
overexpression, and poorly-differentiated SCC lacking any ERBB2 or EGFR 
abnormality. These three populations each had low-level CCND1 amplification and 
nuclear cyclin D1 overexpression. This histological topology and gene amplification 
combinations suggested that genetic instability first produced CCND1 
amplification, and then ERBB2 or EGFR gene amplification occurred. It is further 
speculated that during cancer progression and clonal selection indecisive 
predominance of either clone caused the rare co-amplification of ERBB2 and 


















Esophageal cancer ranks sixth among all cancers in mortality and is the eighth 
most common cancer worldwide. Squamous cell carcinoma (SCC) is the predominant 
histologic type of esophageal cancer worldwide.1 Despite improvements in surgical 
techniques, peri-operative management, and combination therapies involving surgery 
combined with chemotherapy and/or radiotherapy, the prognosis of advanced-stage 
esophageal SCC at remains poor. Therefore, novel therapies (e.g., molecular-targeted 
therapy) are very much needed for patients with esophageal SCC.2 Currently, the most 
promising targets for molecular therapy are amplified ERBB2 and EGFR, which belong 
to the EGFR gene family and encode type I receptor tyrosine kinases (RTKs). Two 
categories of therapies targeting EGFR family members have been or are in clinical 
development: 1) small-molecule inhibitors (e.g., gefitinib, erlotinib, and lapatinib) of 
EGFR family-related tyrosine kinases and 2) humanized antibodies against ERBB2 or 
EGFR (trastuzumab and cetuximab, respectively). There has been some discrepancy in 
findings regarding frequency of EGFR amplification; nevertheless, in our previous 
fluorescence in situ hybridization (FISH) study, the frequency of high-level EGFR 
amplification was 15%,3 and a more recent study using FISH reported the same figure.4 
The frequencies of ERBB2 amplification previously reported were much lower and 
ranged from 2% to 5%.4, 5 Recent comprehensive and semi-comprehensive studies 
examining RTK genes in advanced cancers indicate that amplification of an individual 
RTK gene is usually exclusive; that is, each tumor usually has only one amplified RTK 
gene.1, 2  
Cyclin D1 expressed during the G1-S phase transition of the cell cycle can bind to 
retinoblastoma whose inactivation untethers E2F from inhibitory constraints and 
thereby allows activation of genes required for DNA replication.6 Cyclin D1 
overexpression is significantly associated with cyclin D1 gene (CCND1) amplification, 
which was found to occur in 42%4 or 53% 7 of esophageal SCCs based on FISH 
analyses.  
Multiplex ligation-dependent probe amplification (MLPA) is a new, high-resolution 
method for detecting numerous copy number variations throughout an individual’s 
genome; MLPA assays require only one reaction tube and small amounts of DNA 
extracted from formalin-fixed paraffin-embedded clinical samples.8, 9 Cancer 
progression occurs via a process in which different clones and subclones are produced 
by genetic instability and simultaneously subjected to Darwinian selection. Here, we 
present a case of esophageal SCC in which the clonal profile of ERBB2, EGFR, and 
CCND1 amplification could be accurately and precisely determined via 




 Clinical summary 
A 72-year-old man who had received medical care for hepatitis C presented to the 
Department of Gastroenterologic Surgery, Kanazawa University in September 2012 
describing a sense of constriction in his throat. Upper gastrointestinal examinations 
revealed an advanced SCC in the mid-thoracic esophagus. In January 2013, after one 
course of preoperative chemotherapy (a regimen of docetaxel, cisplatin, and 
fluorouracil), thoracoscopic esophagectomy with cervical, mediastinal, and abdominal 
lymph node dissection and gastric tube reconstruction under laparotomy were 
performed. The postoperative course was uneventful, and recurrence was not found in 
February, 2015. Our laboratory study of this case was approved by the Institutional 
Review Board at Kanazawa University, and written informed consent was obtained 
from the patient. 
Pathological findings 
Surgical specimens 
An ulcerative and infiltrative tumor measuring approximately 4.2×2.7×2.0 cm with 
a superficial lesion extending 5.2 cm in length was found (Fig. 1). Histologically, the 
presented tumor broadly divided two parts, well- and poorly- differentiated SCC: the 
well-differentiated SCC forming cancer pearls (Fig. 2a) was predominant and poorly 
differentiated SCC that occupied the center of the tumor and penetrated the adventitia 
(Fig. 2b). This poorly differentiated SCC contained irregular-shaped necrosis or fibrosis 
occasionally accompanied by foreign-body reaction corresponding to a Grade 1a 
therapeutic effect (Fig. 2c). Metastases of poorly differentiated SCC were evident in 
four regional lymph nodes. Pathological stage was ypIIIB according to the American 
Joint Committee on Cancer (AJCC) criteria. 10 
 
MLPA 
The SALSA MLPA KIT P175-A2 Tumor-Gain (MRC-Holland, Amsterdam, The 
Netherlands) was used for MLPA analysis; this kit contains two or three probes for each 
of 24 genes, including ERBB2, EGFR, and CCND1. A representative tumor area 
approximately 3.0 cm2 was identified in consecutive 6-μm-thick sections that were 
adjacent hematoxylin and eosin (HE)-stained sections. DNA was extracted manually 
according to the manufacturer’s protocol. Data analysis was performed with Coffalyser 
MLPA-DAT software (version 9.4, MRC-Holland) to generate normalized peak values. 
As previously established, peak values below 0.7 were defined as “lost”, those between 
0.7 and 1.3 as “normal”, those between 1.3 and 2.0 as “gain”, and values >2.0 were 
defined as “amplified”.11 
The results showed that ERBB2 and EGFR were amplified; notably, all CCND1 
values were categorized as “gain”. Values for the other 21 genes were within the normal 
range (Table 1). 
 
 
Methods for IHC and FISH 
Antibodies against the internal domain of human ERBB2 (polyclonal, Nichirei, 
Tokyo, Japan; working dilution of 1:100), the external domain of human EGFR 
(Novocastra Lab, Newcastle, UK; working dilution, 1:20), or human cyclin D1 (rabbit 
monoclonal, SP 4, Nichirei, ready-to-use) were used. Antibodies were visualized by 
avidin-biotin binding to peroxidase-conjugated secondary antibodies (Dako, Glostrup, 
Denmark). For evaluation of positive ERBB2 or EGFR staining, a four-tier system (0, 
1+, 2+, or 3+) based on the criteria recommended by Dako for the HercepTestTM was 
used, except that the quantity of positive cells was not considered. For evaluation of 
cyclin D1 staining, only nuclear immunostaining significantly higher than that seen in 
control cells of normal esophageal mucosa were considered to be positive. 
FISH probes for ERBB2 (RP11-62N23), EGFR (RP11-339F13), and CCND1 
(RP11-775J10) were acquired from BACPAC Resources (Oakland, CA, USA) and 
labeled with SpectrumOrangeTM or SpectrumGeenTM with a nick translation kit (Abbott 
Laboratories, Abbott Park, IL, USA). For detection of gene amplification, 
SpectrumGreenTM-labeled pericentromeric probes (Abbott) specific to chromosome 7, 
11, or 17 on which the respective gene was located were co-hybridized with the 
appropriate gene-specific probe to standardize for chromosome number. In order to 
determine the distribution of ERBB2-amplified cells and EGFR-amplified cells, and 
co-localization of CCND1 and ERBB or EGFR, dual–color FISH using two probes 
labeled with different fluorescences was also performed. 
 
Results of IHC and FISH 
Based on IHC, cells with 3+ or 2+ ERBB2 staining were found in well-differentiated 
SCC (Fig. 2a) and mucosal cancer in the tumor margin (Fig.2d); in contrast, the center 
of the tumor that corresponded to poorly differentiated SCC was predominantly 
ERBB2-negative and populated with mostly EGFR 3+ cells. A few nests that were both 
ERBB2-negative and EGFR-negative were also found in the center of the tumor (Fig. 
2b). Small foci of EGFR immunostaining were present in spots throughout the tumor; 
however, staining intensities in these foci did not exceed 2+. Cancer-cell nuclei 
IHC-positive for cyclin D1 were distributed evenly among ERBB2-positive cells, 
EGFR-positive cells, and double-negative cells (Fig. 2e). 
Based on FISH analysis, the IHC ERBB2-positive cells had one to four tightly 
clustered ERBB2 FISH signals, suggesting that amplicons existed in homogeneously 
staining regions (HSR) 12 (Fig. 3a). Each poorly differentiated SCC cells with 3+ EGFR 
IHC staining had one or two large clustered EGFR FISH signals; this pattern also 
suggested that amplification had occurred in HSRs (Fig. 3b). No gene amplification was 
evident in cells with 1+ or 2+EGFR-immunostaining. ERBB2-positive cells and 
EGFR-positive cells were mutually exclusive, and there was no single cell with both 
genes amplified even in areas where the two types of cancer cells were directly apposed 
(Fig. 3c). 
Most cancer-cell nuclei had one to five additional CCND1 signals relative to 
centromere 11 signals, and the ratios of CCND1 copy number to centromere 11 copy 
number ranged from 2.4 to 2.6, suggesting low-level CCND1 amplification (Fig. 3d). 
Dual-color FISH showed that ERBB2-amplified cells (Fig. 3e) and EGFR-amplified 
cells (Fig. 3f) each had co-amplification of CCND1. Metastatic cancer in the lymph 
nodes was cyclin D1-positive, but ERBB2- and EGFR-negative. FISH in these regions 
showed low-level amplification of CCND1. 
Based IHC and FISH analyses, the present tumor consisted exclusively of 
CCND1-amplified cells; of these, 60% exhibited ERBB2 amplification and ERBB2 
overexpression, 30% exhibited EGFR amplification and EGFR overexprssion, and 10% 





The reported frequencies of gene amplification for EGFR and ERBB2 in esophageal 
SCC are 15% 3 and less than 5%,4, 5 respectively, and a large comprehensive study of 
advanced gastric cancers based on single nucleotide polymorphism shows that 
co-amplification of two or more RTK genes in the same tumor fundamentally does not 
occur.9, 13 Our dual-technique study involving MLPA and FISH analysis of advanced 
gastric cancers also supports this conclusion.9 Therefore, the co-amplification of EGFR 
and ERBB2 found in the present case is apparently an exceptionally rare phenomenon. 
However, in these previous studies, 9,12 it is possible that small fractions of amplified 
cells evaded detection due to a dilution effect inherent to studies that involve DNA 
extracted from large tumors. Actually, contrary to these reports of RTK exclusivity, our 
previous dual-technique study involving FISH and IHC using whole-tissue sections 
from gastric cancers showed indications of co-amplification of EGFR and ERBB2; 
however, these data were not statistically significant.14 In our more recent study 
focusing on the co-amplification of ERBB2 and other RTK genes, we found that of 51 
tumors with prominent ERBB2 amplification, 14% (7/51) of the tumors displayed some 
EGFR co-amplification.15 And intriguingly, even in these tumors, the gene 
co-amplification did not occur within individual cells. 
In the present case, three genetically different clones (ERBB2 amplified, EGFR 
amplified, and both–negative) had CCND1 amplification in common. These findings 
suggested that the amplification of either ERBB2 or EGFR occurred after CCND1 
amplification. Because ERBB2 amplification was evident in the carcinoma in situ, it is 
most likely that the ERBB2 amplification occurred before invasion. Probably one of the 
cellular functions induced by the action of cyclin D1 is destabilization of the cellular 
genome,16 and such destabilization could facilitate subsequent ERBB2 or EGFR 
amplification. This hypothesis may be supported by findings from our previous studies 
in which mucosal cancers that were homogeneously positive for MYC alone or MYC 
and CCND1 has small separated foci with ERBB2 or EGFR amplification.15, 17 During 
cancer progression, a single prominent clone with a single RTK gene amplification 
propagates under Darwinian selection to the exclusion of other less prominent clones; 
consequently, advanced cancers do not exhibit co-amplification of RTK genes. However, 
predominance of either of the two clones was apparently not decisive in this chimeric 
SCC; alternatively, pre-operative chemotherapy may have effectively selected against 
the poorly differentiated EGFR-positive clone, which was less differentiated and more 
infiltrative, that might have outcompeted/excluded the ERBB2-amplified clone in the 
absence of the chemotherapy. 
Notably, amplification of RTK genes is not highly characteristic of esophageal SCC 
carcinogenesis. No clear association is evident between RTK amplification and 
clinicopathological parameters: there is no significant difference in the incidence of 
EGFR amplification between Tis/T1 vs T2-4 3, and ERBB2 amplification is unrelated to 
pT, pN, pM, grade, or UICC-status 5. Nevertheless, this EGFR-ERBB2 co-amplification 
may be clinically significant because the overwhelming number of studies on cancers of 
the breast, colon, or stomach demonstrate that these particular RTKs when 
overexpressed because of gene amplification are promising candidates for 
molecular-targeted therapies. 
Fortunately, in the present case, because of the chemotherapy-surgery combination, 
the cancer was resectable, and no recurrence has been found. However, if the cancer 
recurs, one therapeutic option may be molecular-targeted therapy. In this case, 
theoretically lapatinib, a dual tyrosine-kinase inhibitor with activity against EGFR and 
ERBB2, could be used first. There is evidence that increased cyclin D expression 
provides resistance to therapies directed at EGFR.18 In head and neck SCC cell lines, 
overexpression and /or amplification of CCND1 is associated with decreased efficacy of 
the selective EGFR tyrosine-kinase inhibitor gefitinib. 19 Although it is in the early stage 
of clinical trials for lung cancer, a cyclin D1-repressing rexanoid bexarotene enhances 
the effect of the EGFR inhibitor erlotinib. Therefore, it is possible that co-amplification 
of CCND1 and EGFR could be an important target of this combination therapy. 20 
In conclusion, the relatively rare oncogenic change found this case gave us an 
important insight into the clonal evolution of esophageal SCC and also provided us 






This work was financially supported by the Japanese Ministry of Education, Sports, 
Science and Culture [C25460452 (AO), and Young Scientists (B) (25860266) (TO) and 
(26860235) (RN)]  
Disclosure Statement 
 






1 Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol 2013; 19: 
5598-606. 
2 Kono K, Mimura K, Fujii H, Shabbir A, Yong WP, Jimmy So A. Potential 
therapeutic significance of HER-family in esophageal squamous cell carcinoma. Ann 
Thorac Cardiovasc Surg  2012; 18: 506-13. 
3 Hanawa M, Suzuki S, Dobashi Y, et al. EGFR protein overexpression and gene 
amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006; 118: 
1173-80. 
4 Sunpaweravong P, Sunpaweravong S, Puttawibul P, et al. Epidermal growth 
factor receptor and cyclin D1 are independently amplified and overexpressed in 
esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2005; 131: 111-9. 
5 Reichelt U, Duesedau P, Tsourlakis M, et al. Frequent homogeneous HER-2 
amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol  
2007; 20: 120-9. 
6 Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and 
E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 
1993; 75: 495-505. 
7 Ying J, Shan L, Li J, et al. Genome-wide screening for genetic alterations in 
esophageal cancer by aCGH identifies 11q13 amplification oncogenes associated with 
nodal metastasis. Plos One 2012; 7: e39797. 
8 Moelans CB, de Weger RA, van Blokland MT, et al. HER-2/neu amplification 
testing in breast cancer by multiplex ligation-dependent probe amplification in 
comparison with immunohistochemistry and in situ hybridization. Cell Oncol 2009; 31: 
1-10. 
9 Ooi A, Oyama T, Nakamura R, Tajiri R, et al. Semi-comprehensive analysis of 
gene amplification in gastric cancers using multiplex ligation-dependent probe 
amplification and fluorescence in situ hybridization. Mod Pathol. 2015. accepted and in 
press 
10 Flemming ID, Cooper IS, HensonDE et al., eds. Esophagus. In: American Joint 
Committ on Cancer, Cancer Staging Manual, 5th edn, ch. 9 Philadelphia, PA: lippincott 
Williams and Wiklins, 1997;65-69 
11 Ooi A, Inokuchi M, Harada S, et al. Gene amplification of ESR1 in breast 
cancers--fact or fiction? A fluorescence in situ hybridization and multiplex 
ligation-dependent probe amplification study. J Pathol 227: 8-16. 
12 Kobayashi M, Ooi A, Oda Y, Nakanishi I. Protein overexpression and gene 
amplification of c-erbB-2 in breast carcinomas: a comparative study of 
immunohistochemistry and fluorescence in situ hybridization of formalin-fixed, 
paraffin-embedded tissues. Hum Pathol 2002; 33: 21-8. 
13 Deng N, Goh LK, Wang H, et al. A comprehensive survey of genomic 
alterations in gastric cancer reveals systematic patterns of molecular exclusivity and 
co-occurrence among distinct therapeutic targets. Gut 2012; 61: 673-84. 
14 Mitsui F, Dobashi Y, Imoto I, et al. Non-incidental coamplification of Myc and 
ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol 2007; 20: 622-31. 
15 Tajiri R, Ooi A, Fujimura T, et al. Intratumoral heterogeneous amplification of 
ERBB2 and subclonal genetic diversity in gastric cancers revealed by multiple 
ligation-dependent probe amplification and fluorescence in situ hybridization. Hum 
Pathol 2014; 45: 725-34. 
16 Albertson DG. Gene amplification in cancer. Trends Genet 2006; 22: 447-55. 
17 Ooi A, Suzuki, S., Nakazawa, K., Itakura, J., Imoto, I., Nakamura, Y., Dobashi, 
Y. Gene amplification of Myc and its coamplification with ERBB2 and EGFR in 
gallbladder adenocarcinoma. Anticancer Res 2009; 29: 19-26. 
18 Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL. Cyclin D as 
a therapeutic target in cancer. Nature Rev Cancer 2011; 11: 558-72. 
19 Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA. 
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective 
epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck 
squamous cell carcinoma cell lines. Clin Cancer Res 2004; 10: 7764-74. 
20 Dragnev KH, Ma T, Cyrus J, et al. Bexarotene plus erlotinib suppress lung 
carcinogenesis independent of KRAS mutations in two clinical trials and transgenic 








Resected esophagus. An ulcerative and infiltrative tumor from the thoracic 
esophagus (a). Cut surfaces show the tumor invaded the adventitia (b). 
 
Figure 2 
Results from immunohistochemistry (IHC) and a figure showing chemotherapeutic 
effects. Well-differentiated squamous cell carcinoma (SCC) was positive for ERBB2 
(a); the poorly differentiated SCC was EGFR-positive, or both ERBB2- and 
EGFR-negative (b).  Necrotic cancer nests with foreign body reaction were found (c). 
Mucosal cancer was also positive for ERBB2 (d). Cyclin D1-positive nuclei were 
scattered evenly throughout the tumor (e). 
 
Figure 3 
Results of fluorescence in situ hybridization (FISH). The ERBB2-positive cells and the 
EGFR-positive cells had clustered signals of ERBB2 (a: orange signals, ERBB2; green 
signals, centromere 17) or EGFR (b: orange signals, EGFR; green signals, centromere 
7), respectively. Based on dual-color FISH images, no single individual cell had both 
types of amplification (c: green signals, ERBB2; orange signals, EGFR). Most cancer 
cells showed increased CCND1 copy number relative to centromere 11 copy number. (d: 
orange signals, CCND1; green signals, centromere 11). Dual-color FISH demonstrated 
that ERBB-2-amplified cells and EGFR-amplified cells each had co-amplification of 
CCND1 (e: green signals ERBB2; orange signals, CCND1. f: green signals, EGFR; 





Name of gene (chromosomal locus )
Probe location Exon 8 Exon 22 Exon 2 Exon3 Exon 5 Exon 7 Exon 29
3.23 3.14 1.45 1.54 1.37 5.62 9.51
Table 1 MLPA peak values
 EGFR (7p11.2) CCND1(11q13.3)  ERBB2 (17q12)
